Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930641 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
NCT03930641 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 34 participants.
The verdict
NCT03930641, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
Study Summary
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.
Interventions
- DRUG RTH258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-23 |
| Est. Completion | 2019-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03930641
The ClinicalTrials.gov registry entry for NCT03930641 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RTH258 is the first listed.
NCT03930641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03930641 about?
NCT03930641 is a clinical study titled "Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration". This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations of the prefilled syringe use for intravitreal injection.
What is the current status of trial NCT03930641?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2019-05-23. Estimated completion is 2019-07-02.
What interventions are being tested in trial NCT03930641?
The interventions under investigation include: RTH258 (DRUG).
Who is sponsoring clinical trial NCT03930641?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.